Sales of Merck’s drug Keytruda have grown beyond those of Bristol-Myers Squibb’s Opdivo, to become the global leading PD-1 inhibitor.
List view / Grid view
Filter the results
Researchers have developed a series of lipid nanoparticles, which encapsulate RNA, for effective and improved vaccine delivery.
A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study.
An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial...
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
Investigational therapy directly kills tumour cells and unmasks them to the body's defences.
Adjuvant nivolumab has been found to be more superior than ipilimumab in the standard of care in patients with surgically resected stage III/IV melanoma...
Alternative immunotherapy drug nivolumab is more effective than current standard of care in treating advanced melanoma after surgical removal of disease.